The introduction of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable buzz within the medical community. This innovative dual GIP and GLP-1 agonist medication suggests to offer notable improvements in weight reduction compared to existing therapies. Preliminary patient studies have demonstrated marked reductions in weight , po